Related Experiment Video

Updated: Aug 12, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

The Ras-Raf-MEK-ERK pathway in the treatment of cancer

R A Hilger1, M E Scheulen, D Strumberg

  • 1Department of Internal Medicine and Medical Oncology, West German Cancer Center, University Medical School of Essen, Germany.

Onkologie
|February 5, 2003
PubMed

Insights

Mitogen-activated protein kinases (MAPKs) regulate cell functions and are key in transmitting signals from Ras to the nucleus. Targeting the MAPK pathway offers a promising strategy for developing novel, less toxic anti-cancer drugs.

Area of Science:

  • Cellular Biology
  • Molecular Biology
  • Oncology

Background:

  • Mitogen-activated protein kinases (MAPKs) are crucial signaling proteins regulating cell growth, division, and death.
  • MAPKs translocate to the nucleus upon activation, phosphorylating nuclear proteins and mediating extracellular growth signals from Ras.
  • The MAPK pathway involves a cascade of phosphorylation events mediated by Raf, MEK (MAP kinase kinase), and ERK (MAP kinase).

Purpose of the Study:

  • To review the rationale for targeting the MAP kinase pathway in cancer therapy.
  • To discuss the current status of pharmacological approaches targeting the MAPK pathway.
  • To explore the potential of MAPK pathway inhibitors as novel, target-specific anti-cancer drugs.

Main Methods:

  • Literature review of studies on the MAPK pathway and its role in cancer.
  • Analysis of current clinical investigations of drugs targeting Ras, Raf, or MEK.
  • Discussion of the therapeutic potential and challenges of targeting the MAPK pathway.

Main Results:

  • The MAPK pathway is a critical route for Ras-mediated extracellular signal transmission to the nucleus.
  • Inhibitors of Ras, Raf, or MEK are under clinical investigation as anti-cancer agents.
  • Targeting the MAPK pathway presents opportunities for developing less toxic, target-specific cancer therapies.

Conclusions:

  • The MAPK pathway is a validated target for anti-cancer drug development.
  • Pharmacological inhibition of key kinases in the MAPK pathway shows promise for cancer treatment.
  • Further research and clinical trials are essential to optimize MAPK-targeted therapies.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...